TIL Therapies Gain Traction in Solid Tumor Treatment

Tumor-infiltrating lymphocyte (TIL) therapies are gaining traction as a promising approach for treating solid tumors, especially following the FDA’s recent approval of the first autologous cell therapy for melanoma.  With more than 75 candidates in the pipeline, the spotlight is now on the infrastructure needed to support clinical development and commercial readiness.

In a recent article published by In Vivo titled “With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space”, Project Farma CEO Anshul Mangal shares expert insights on the manufacturing challenges and opportunities ahead for TIL therapies.  He emphasizes the importance of scalable solutions, automation, early investment, and regulatory alignment to ensure these advanced therapies reach patients efficiently.

Read more about how TIL therapies are evolving and what it will take to bring them to scale here. Subscription required.